introduction Sunitinib is a standard first-line antiangiogenic agent for metastatic renal cell carcinoma (mRCC). The approved sunitinib administration schedule consists of daily dosing at 50 mg for 4 weeks, followed by 2 weeks' rest (schedule 4/2). Sunitinib treatment with schedule 4/2 can result in clinically significant adverse events. In phase III trials comparing sunitinib with interferon-α or pazopanib, 54%-63% of patients treated with sunitinib experienced fatigue (11%-17% for grade 3-4), 57%-61% had diarrhea (8%-9% for grade 3-4), 27%-30% had stomatitis, and 29%-50% had handfoot syndrome (9%-11% for grade [3] [4] . Furthermore, grade 3-4 neutropenia and thrombocytopenia developed in 16%-19% and 8%-22% of patients, respectively [1, 2] . These toxicities result in dose delay (38%-49%) or dose reduction (50%-51%) [1, 2] , compromising dose intensity and decreasing drug exposure, which is essential for achieving optimal treatment outcomes [3] . In addition, ∼20% of patients eventually discontinue sunitinib because of adverse events [1, 2] . In studies including patients with Asian ethnicity, the incidence of toxicity tends to be higher, resulting in more frequent dose modifications [4] [5] [6] .
In phase I studies of sunitinib [7] [8] [9] , 117 patients with solid tumors underwent various treatment and dosage regimens. Of the regimens tested, 50 mg sunitinib with a 4/2 schedule was selected for further clinical trials based on the limited efficacy data achieved in a very limited number of enrolled patients [8, 9] , which left room for further studies on the optimal dosing schedule. Since December 2006, shortly after the introduction of sunitinib in Korea, we have used a 2/1 schedule, comprising a 2-week treatment period, followed by 1 week's rest, for patients who could not tolerate 25 mg/day or who develop intolerable toxicities during weeks 2-3. The 2/1 schedule seemed highly tolerable and led patients to continue treatment without interruption or further dose reduction [4] . During this period, a phase I study on a sunitinib 2/1 schedule reported that exposure to sunitinib and its active metabolites was comparable with that of a 4/2 schedule, with a more favorable toxicity profile [10] .
On the basis of these studies and our clinical experience, we conducted a randomized phase II study of patients with mRCC to determine the efficacy and safety of the 2/1 schedule versus the standard 4/2 schedule.
patients and methods patients
To be enrolled, patients had to have histologically confirmed RCC with clearcell components and recurrent or metastatic disease. Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 was required, but patients with evaluable lesions without target lesions were eligible. Patients had to have an Eastern Cooperative Oncology Group performance score of 0-2 and adequate organ function. Exclusion criteria included central nervous system metastases, prior treatment with vascular endothelial pathway inhibitors, and any serious medical conditions that may interfere with the interpretation of study results (supplementary Data Protocol, available at Annals of Oncology online). The protocol was approved by each participating institutional review board, and all patients provided written informed consent.
study design and end points
This was a randomized, open-label, multicenter, phase II trial (registered at clinicaltrials.gov as NCT00570882) carried out at three centers in Korea.
Eligible patients were randomly assigned (1:1) by a computer-generated allocation schedule after stratification according to risk groupings (favorable, intermediate, and poor) based on Memorial Sloan Kettering Cancer Center (MSKCC) risk criteria [11] and the presence or absence of measurable lesions. The primary end point was the failure-free survival (FFS) rate (%) at 6 months, which measures both efficacy and tolerability. Failure was defined as discontinuation of the assigned treatment for any reason including disease progression, treatment toxicity, patient refusal, and death. Secondary end points were the objective response rate (ORR), safety, time-to-treatment failure (TTF), time to progression (TTP), and overall survival (OS).
treatment and evaluation procedures
Patients assigned to schedule 4/2 received sunitinib (50 mg), orally, on a standard 4 weeks on and 2 weeks off schedule, whereas those assigned to schedule 2/1 received sunitinib on a 2 weeks on and 1 week off schedule. In either arm, dosage could be interrupted or reduced (to 37.5 mg/day and then to 25 mg/day) depending on the type and severity of individual toxicities encountered (supplementary Data Protocol, available at Annals of Oncology online). If patients could not tolerate 25 mg/day, they were removed from the study. However, for patients allocated to schedule 4/2, crossover to schedule 2/1 was allowed when patients could not tolerate 25 mg/day or when patients wanted to change the schedule rather than undergo dose reduction or interruption.
Baseline tumor assessments were carried out ≤21 days before randomization. On-treatment tumor assessment was carried out every 6 weeks (±7 days) until 48 weeks after randomization. With the exception of patients who experienced disease progression <24 weeks after randomization, all patients who continued to receive treatment were assessed for their response at 24 weeks regardless of treatment delays. For patients whose disease did not progress by 48 weeks after randomization, responses were assessed every 12 weeks. Response was assessed according to RECIST 1.0 by investigators and independently by an external reviewer blind to the assigned schedule.
Safety and tolerability were assessed by physical examination and laboratory testing, which were carried out on day 1, day 14, and day 28 of the first cycle, and then on day 1 and day 28 for schedule 4/2, and on day 1 and day 14 of the treatment cycle for schedule 2/1. Toxicity was graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events version 3.0.
statistical plan
A randomized two-arm phase II design was constructed to select the optimal schedule with the highest 6-month FFS, irrespective of the difference. To obtain at least 90% probability of selecting the optimal schedule when the absolute difference in true FFS rate is 15% or greater with an expected 6 month FFS of 60% in the 4/2 schedule, 36 assessable patients were required for each arm [12] . The response, dose reduction, and toxicities in the two treatment arms were compared using the ). FFS at 6 months was higher with schedule 2/1 (63%; 24/38) than with schedule 4/2 (44%; 16/36). Median TTF was 7.6 months for schedule 2/1 and 6.0 months for schedule 4/2 (P = 0.029, Figure 1 ). Eight patients (23%) on schedule 4/2 crossed over to schedule 2/1 because of toxicity. The clinical courses of patients who crossed over from schedule 4/2 to schedule 2/1 are summarized in supplementary Table S1 , available at Annals of Oncology online. After crossover, the last prescribed dose could be maintained, and a majority of preceding grade 2 or worse toxicities did not occur. In the schedule 2/1 and schedule 4/2 groups, 32% and 47% of patients, respectively, experienced at least one dose reduction. The time to first dose reduction was significantly longer on schedule 2/1 than on schedule 4/2 (P = 0.014; supplementary Figure S2 , available at Annals of Oncology online); the proportion of patients who underwent dose reduction within 6 months after initiation was 21% in schedule 2/1 and 50% in schedule 4/2 (P = 0.009).
safety Treatment-emergent adverse events are listed in Table 2 . Neutropenia and fatigue were more frequent with schedule 4/2 than with schedule 2/1 (P = 0.037, P = 0.017, respectively). Common adverse events that were reported less frequently with schedule 2/1 than with schedule 4/1 included stomatitis of any grade and stomatitis of grade 3-4, rash of any grade, and handfoot syndrome of grade 3-4. Figure S3 , available at Annals of Oncology online). At the data cutoff, 58 patients experienced disease progression, and 48 patients had died. The median TTP was 12.1 months with schedule 2/1 and 10.1 months with schedule 4/2 ( Figure 2 ). The median OS was 30.5 months with schedule 2/1 and 28.4 months with schedule 4/2 (supplementary Figure S4 , available at Annals of Oncology online). For eight patients who switched from schedule 4/2 to schedule 2/1 due to toxicity, the median TTP was 29.3 months (supplementary Figure S5 , available at Annals of Oncology online, P = 0.004).
discussion
Our RESTORE trial revealed that patients treated with schedule 2/1 had a higher FFS at 6 months than those treated with schedule 4/2, with a significantly longer TTF. Our study also showed that schedule 2/1 was more tolerable than schedule 4/2 as clinically significant adverse events were less common with schedule 2/1. Consequently, fewer patients on schedule 2/1 required dose reductions in the first 6 months, and the time to dose reduction was significantly prolonged in schedule 2/1. When patients on schedule 4/2 switched to schedule 2/1 because of intolerable toxicities, the majority of adverse events reduced in severity or never recurred, and disease control was maintained in the majority of patients. In efficacy end points, the ORRs, DoR, median TTP, and OS were numerically better in schedule 2/1. 
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Sunitinib administered orally on a 4/2 schedule was employed as the standard dosing schedule for phase II and III trials [8, 9] . A pharmacologic study demonstrated that patients with the highest sunitinib exposure experienced an improved response, longer TTP, and prolonged OS [3] . Thus, maintaining adequate sunitinib dosing and drug levels is essential for the optimal oncologic outcome. However, maintenance of sunitinib dose intensity is challenging because of treatment-related adverse events; 40%-50% of patients experienced dose interruption and 50% required dose reduction, while 20% of patients discontinued sunitinib because of adverse events. To improve the efficacy of sunitinib, the incidence and severity of adverse events should be reduced, and compliance should be improved.
Alternative sunitinib schedules have attempted to improve drug tolerance and efficacy. A randomized phase II trial comparing the standard 4/2 schedule with 37.5 mg continuous daily dosing (CDD) demonstrated no difference in survival, drug tolerance, or quality of life, but showed a strong trend suggesting CDD was inferior to a 4/2 schedule in terms of TTP [14] . When patients receive daily sunitinib, adverse effects start to appear between weeks 2-3 and usually worsen during weeks 3-4. Accordingly, quality-of-life scores demonstrate a cyclic pattern, declining in the latter 2 weeks of each treatment cycle and typically improving after each 2-week break [14] . Even after patients enter into the off-treatment period, some adverse events, including edema and anemia, tend to be aggravated between week 4 and week 5, and do not fully recover until day 42 [2] . Considering the temporal sequence of toxicity development, the provision of a drug-free interval in the third week of the drug cycle may reduce the incidence and severity of adverse reactions. A phase I study of 2 weeks on and 1 week off sunitinib dosing showed that the 2/1 schedule provided prolonged drug exposure compared with that of the 4/2 schedule, with a favorable toxicity profile, especially for fatigue [10] . While the RESTORE trial was ongoing, several retrospective studies on the 2/1 schedule were reported [15, 16] , which consistently showed that alternative dosing of sunitinib was associated with less toxicity and a lower incidence of dose interruption or dose reduction [15] [16] [17] . Furthermore, several studies demonstrated that a 2/1 schedule was associated with significantly improved progression-free survival and OS [16, 17] . In the RESTORE trial, the 2/1 schedule was associated with less toxicity, especially neutropenia, fatigue, stomatitis, and hand-foot syndrome. Consequently, fewer patients in the 2/1 schedule required dose reductions, especially during the first 6 months after initiation of treatment. In contrast to the retrospective study results, we did not observe a trend toward improved TTP and OS with the 2/1 schedule. Interestingly, when TTP was compared among three groups, namely, the schedule 2/1 group, a subgroup of schedule 4/2 including those who never switched over to schedule 2/1, and the other 4/2 subgroup including those who switched to schedule 2/1, there was a statistically significant difference (supplementary Figure S3 , available at Annals of Oncology online). This may be caused by the fact that the patients who switched to the 2/1 schedule were those who had experienced intolerable toxicities, which can be a biomarker for an improved outcome, and if patients achieved a positive response to sunitinib, then physicians will try to continue treatment for a longer time period by managing adverse events with dose or schedule modifications. This potential bias rather than the schedule per se might explain the improved TTP and OS in the retrospective studies [18] .
In our RESTORE study, the 2/1 schedule was associated with a numerically higher ORR and deeper DoR. Recently, a pharmacodynamic (PD) study on patients with sunitinib in a 4/2 schedule showed that maximum antiangiogenic activity was achieved after 14 days on sunitinib with no further reduction from day 14 to 28, and most patients showed rebound tumor blood flow after a 2-week treatment break [17] , which could be avoided in part with a 2/1 schedule. A phase I study of sunitinib also showed that sunitinib blood concentrations reach a steady state within 14 days of treatment, and sunitinib and its active metabolites were detectable after a 7-day break, which could provide prolonged drug exposure, in contrast to complete elimination after the 2 weeks off drug period of the 4/2 schedule [7, 8, 10] . This finding is also consistent with results from a population pharmacokinetic (PK)/PD model of sunitinib and SU012662 using pooled PK/PD data of patients treated with sunitinib, which predicted that the overall average plasma exposure to sunitinib and its active metabolite over a full cycle (42 days) was similar between the 2/1 schedule and 4/2 schedule (Pfizer data on file). These phase I and PK/PD modeling data support a numerically higher, at least comparable, ORR and DoR for schedule 2/1.
The major limitations of our RESTORE trial include the small sample size, powered only to select the schedule with higher FFS and not to detect differences in ORR, TTP, and OS, and its openlabel nature, which may lead to bias as patients may switch over to the other arm preferentially on the 4/2 schedule.
In conclusion, sunitinib administered in a 2/1 schedule is associated with less toxicity and higher FFS at 6 months than in a 4/2 schedule, without compromising efficacy. Patients on a 4/2 schedule who experience intolerable toxicities could switch to a 2/1 schedule, which would likely improve tolerability while preserving efficacy.
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